Susanne Eder-Lingelbach | VP Clinical Development
Valneva

Susanne Eder-Lingelbach, MSc, MBA, is leading Valneva´s global Clinical Development organization based in Vienna, Austria and as Vice President a member of the company´s leadership team. Valneva is a public, fully integrated, specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need (www.valneva.com). Susanne has 20 years of experience in clinical development with a strong emphasis on vaccine development. Her broad clinical development experience includes different clinical development approaches (such as correlate, surrogate, challenge trials, efficacy trials) across different populations (healthy volunteers, ICU patients; pediatric, adult, elderly population). She has been accountable for the design and/or execution of more than 20 clinical product development projects from Phase 1 to Phase 4 in various indications. It included vaccine candidates to protect against Japanese Encephalitis, Pseudomonas Aeruginosa, Lyme Borreliosis, COVID-19, Zika and Chikungunya. Development programs were run in close alignment with various regulatory agencies (including US FDA, EMA, MHRA) with clinical trials executed globally (e.g., US, Europe, UK, The Philippines, Brazil, Australia, New Zealand). Under Susanne’s clinical leadership, Valneva successfully achieved two regulatory approvals – the first COVID-19 vaccine that received an ordinary Marketing Authorization by the European Medicines Agency (EMA) and the world´s first Chikungunya vaccine which was approved by the US FDA in November 2023.